What Company Owns Wegovy — and Why It Matters for UK Patients

How Novo Nordisk brought semaglutide from diabetes treatment to licensed weight-loss medicine

Novo Nordisk's route to Wegovy began with semaglutide's development as a diabetes drug. The company first launched semaglutide as Ozempic (a weekly injection for type 2 diabetes) before its researchers recognised the compound's pronounced effect on body weight. That observation led to the STEP programme: a series of large clinical trials testing higher-dose semaglutide specifically for weight management in people without diabetes.

The STEP 1 trial, published in the New England Journal of Medicine, randomised 1,961 adults with obesity and found an average body-weight reduction of around 15% over 68 weeks at the 2.4 mg maintenance dose, alongside lifestyle intervention. Those results supported Novo Nordisk's regulatory submissions worldwide. The MHRA granted the UK marketing authorisation for Wegovy as a weight-management medicine, and it carries a Black Triangle (▼) designation, meaning the MHRA collects enhanced safety data on an ongoing basis.

Novo Nordisk has since expanded the Wegovy range: a 7.2 mg single-dose pen was approved by the MHRA on 14 April 2026, and the oral tablet formulation followed on 11 June 2026, the first oral GLP-1 medicine licensed for weight loss anywhere in Europe. You can read more about the full Wegovy treatment range to see how these options differ in practice.

Ozempic, it is worth being clear, remains licensed solely for type 2 diabetes in the UK. The MHRA has not authorised it for weight management, and presenting it as a weight-loss medicine would be outside its licensed use.

Why the company behind Wegovy matters when you're buying online

Knowing that Novo Nordisk manufactures Wegovy is not just trivia. It is the practical starting point for spotting counterfeit supply. Genuine Wegovy pens enter the UK through Novo Nordisk's authorised wholesale distribution chain, which means they are dispensed only by pharmacies holding a valid GPhC registration and operating under MHRA-regulated conditions.

The MHRA has issued repeated public warnings about fake weight-loss pens sold via social media and unregistered online sellers. In October 2025, enforcement teams raided a UK site producing counterfeit tirzepatide pens, and by that point approximately 20 million doses of illegally traded weight-loss medicines (estimated street value around £45 million) had been seized. Fake pens have been found to contain insulin rather than the stated active ingredient, with predictable consequences for anyone who injected them.

The safest check is simple: any pharmacy dispensing Wegovy in the UK should appear on the GPhC register. You can verify any online pharmacy at pharmacyregulation.org/registers. If a seller cannot be found there, or offers Wegovy without a clinical assessment, that is a serious warning sign. Report suspect sellers through the MHRA Yellow Card scheme. For further background on the company behind Wegovy's UK supply, that page covers the authorised distribution chain in more detail.

Wegovy's cost in the UK context, and what Novo Nordisk's pricing means for patients

As a Danish pharmaceutical company founded in 1923, Novo Nordisk sets Wegovy's wholesale list price, and private pharmacies price their services around it. Since Eli Lilly raised Mounjaro's UK list price from around September 2025, the private market for both medicines has settled into a broadly comparable range. Reported private prices for Wegovy typically sit somewhere between £149 and £375 per month depending on dose and provider, though those figures shift; the Wegovy cost page covers current context in more detail.

On the NHS, NICE has recommended semaglutide (Wegovy) under TA875, but access is limited to specialist weight management services and a maximum treatment duration of two years. Waiting lists in many areas remain long. That gap between NICE recommendation and practical NHS availability is why many people look at regulated private routes instead.

Novo Nordisk also makes Rybelsus (oral semaglutide tablets at 3 mg, 7 mg and 14 mg) but those strengths are licensed for type 2 diabetes, not weight loss. The Wegovy tablet steps (1.5 mg, 4 mg, 9 mg, 25 mg) are a separate, distinct product with a different licence. If you are exploring semaglutide options for weight management, the distinction matters for both clinical and legal reasons.

If you order through a regulated private service on a Monday before noon, delivery typically arrives on Tuesday, a detail worth bearing in mind around bank holidays, when the next working day shifts. Treatment through nume means a named GPhC-registered prescriber reads your consultation answers, not software, and dispatch follows the same day where clinically appropriate.

If you would like to explore whether Wegovy or another licensed weight-loss treatment is suitable for you, start your free consultation with our prescribing team.